Benzinga  6 hrs ago  Comment 
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has initiated a phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) in combination with Opdivo (nivolumab) for patients with relapsed or refractory Hodgkin lymphoma (HL) after...
Market Intelligence Center  Sep 24  Comment 
A covered call identified by MarketIntelligececenter.com's patented algorithm on Seattle Genetics Inc. (SGEN) could yield about 9.72% (41.75% annualized, for comparison purposes only) in 85 days. Pair a long position in the stock with the Dec. '15...
Benzinga  Sep 16  Comment 
On late Tuesday, hedge fund Baker Bros. Advisors, managed by Julian and Felix Baker, filed two Schedule 13Ds with the SEC, disclosing moves in DBV Technologies SA - ADR (NASDAQ: DBVT) and Seattle Genetics, Inc. (NASDAQ: SGEN). The firm disclosed...
newratings.com  Sep 11  Comment 
WASHINGTON (dpa-AFX) - Seattle Genetics Inc. (SGEN) has offered to sell about 11.71 million shares of its common stock to the public at a price of $41.00 per share. The underwriters of the offering have been granted a 30-day option to purchase up...
Benzinga  Sep 10  Comment 
Seattle Genetics, Inc. (NASDAQ: SGEN) today announced the pricing of an underwritten public offering of 11,707,318 shares of its common stock at a price to the public of $41.00 per share. All of the shares are being sold by...
Market Intelligence Center  Aug 27  Comment 
Seattle Genetics Inc. (SGEN) presents a trading opportunity that offers a 8.23% return in just 113 days. A covered call on Seattle Genetics at the $40.00 level expiring on Dec. '15 offers an assigned return rate of 8.23% or 26.57% annualized....
Market Intelligence Center  Aug 21  Comment 
For a hedged play on Seattle Genetics Inc. (SGEN), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Dec. '15 $42.00 covered call for a net debit in the $38.51 area. That is also the break-even stock price for the...
FiercePharma  Aug 18  Comment 
Seattle Genetics just won a boost for its lymphoma drug Adcetris. The FDA added a new indication to the drug's toolbox, for patients with Hodgkin's lymphoma at high risk of relapse after a stem-cell transplant.


Seattle Genetics, Inc. is a biotechnology company developing monoclonal antibody-based therapies for treating cancer and autoimmune disease.[1] The company is working to develop next generation monoclonal therapies called antibody-drug conjugates (ADCs). The technology links potent synthetic drugs with monoclonal antibodies. The company has collaborations with major industry players all over the world such as: Millennium Pharmaceuticals, Bayer AG (BAYRY), Celldex Therapeutic (BER:TCE1), GlaxoSmithKline (GSK), Genentech (DNA), and quite a few others.[1] Leveraging these collaborations the company is working to navigate the high development costs and regulations that are indicative of the drug industry.

Business Growth

Seattle Genetics does not have any commercial products yet, but had revenue of $107.5 million for 2010. This was an increase of 107% from 2009. The company derived its revenue from payments that included technology access and maintenance fees, milestone and reimbursement payments from its collaborations. Its large jump from 2009 was primarily due to payments received from its collaborations with Genentech, Millennium, and other ADC collaborations.[1]

Trends and Forces

High Costs of Drug Development make it Difficult for Small Companies like Seattle Genetics

For more detailed information on the FDA approval process, see also Clinical trials.

Developing a new drug is a time-consuming and costly endeavor. Hundreds of thousands of candidate compounds must be screened to identify a handful of potential drugs, and even fewer of these candidate drugs are found to be effective at treating a disease. The drug must then pass strict safety standards in several series of clinical trials. The entire process of developing a new drug and bringing it to the market takes up to 10 to 15 years and on average costs $1.3 billion.[2]

Tightening Food and Drug Administration (FDA) Regulations

Beginning in 2009, the FDA implemented a series of reforms that include stricter monitoring of drug adverse events, more funding for the agency, stronger ability to force product recalls, more scientific expertise within the agency, more transparency. Even before 2009 the result has been a much more conservative FDA, demanding more product information.[3]


The various aspects of patent protection and the extremely high costs of researching and developing drugs marks the pharmaceutical industry with high risk and high competitiveness. It is important to keep in mind when considering a comparison of industry players that competition does not arise between each company as a whole, but rather between specific drug areas and their relative advantages in therapeutic treatment. Due to this fact many of Seattle Genetic's collaborators are competitors since they are developing therapies in similar disease areas. They include:


  1. 1.0 1.1 1.2 Seattle Genetics 2010 10k
  2. DiMasi, Joseph, “The Cost of Biopharmaceutical R&D: Is Biotech Different?,” Managerial and Decision Economics, 2007
  3. The FDA: A tough tonic
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki